FDA Expands Approval of Delandistrogene Moxeparvovec-rokl for Duchenne Muscular Dystrophy
June 21st 2024After being previously approved in June 2023 under an Accelerated Approval process, the FDA has granted an expanded approval for non-ambulatory individuals and individuals 4 years of age or older.
Read More